Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Lapatinib plus trastuzumab
Sponsor: Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.
Collaborators: OnkoDataMed GmbH